<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05797597</url>
  </required_header>
  <id_info>
    <org_study_id>AERD-CoV19</org_study_id>
    <nct_id>NCT05797597</nct_id>
  </id_info>
  <brief_title>Long-term Aspirin Therapy as a Predictor of Decreased Susceptibility to SARS-CoV-2 Infection in Aspirin-Exacerbated Respiratory Disease</brief_title>
  <acronym>AERD-CoV19</acronym>
  <official_title>Long-term Aspirin Therapy as a Predictor of Decreased Susceptibility to SARS-CoV-2 Infection in Aspirin-Exacerbated Respiratory Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lucyna Mastalerz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jagiellonian University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aspirin-exacerbated respiratory disease (AERD) is characterized by the presence of asthma,&#xD;
      chronic rhinosinusitis with nasal polyposis (CRwNP), and acute respiratory reactions induced&#xD;
      by aspirin and other cyclooxygenase-1 inhibitors. One of the well-established therapeutic&#xD;
      options is aspirin desensitization followed by daily aspirin therapy. The potential&#xD;
      mechanisms underlying the clinical benefit of this approach include the downregulation of&#xD;
      CysLT1 receptor, inhibition of PGD2 and interleukin IL-4 via the signal transducer and&#xD;
      activator of transcription 6, global (blood, urine) activation of type 2 (T2) inflammation as&#xD;
      well as local (sputum) reduction of T2 asthma inflammation. Indeed, among current&#xD;
      aspirin-treated patients with AERD (n=37), no one had severe acute respiratory syndrome&#xD;
      coronavirus clade 2 (SARS CoV-2) infection and most importantly, none of them developed&#xD;
      COVID19 during pandemic. WHY? Notably, patients with AERD did not have asthma and nasal&#xD;
      polyps exacerbation on aspirin, which is in line with other studies. Respiratory infections,&#xD;
      such as the current COVID-19 pandemic, target epithelial cells in the respiratory tract.&#xD;
      SARS-CoV-2 spike (S) protein binds angiotensin-converting enzyme 2 (ACE2), and in concert&#xD;
      with host proteases, principally transmembrane serine protease 2 (TMPRSS2), promotes cellular&#xD;
      entry. Nasal and bronchial epithelium play a key role in the early phases of an immune&#xD;
      response to respiratory viruses. Induced sputum (IS) and nasal lavage (NL) cells are likely&#xD;
      the first immune cells to encounter SARS CoV-2 during an infection, and their reaction to the&#xD;
      virus will have a profound impact on the outcome of the infection. Interferons (IFNs) are&#xD;
      antiviral cytokines and among the first mediators produced upon viral infection. IFNs are&#xD;
      divided into three groups based on their receptor usage; type I IFNs (IFN-α and IFN-β), type&#xD;
      II IFN (IFN-γ), and type III IFNs (IFN-λ1 and 2). Both production of IFN and cellular&#xD;
      response to IFN are critical steps for the restriction of viral dissemination. An&#xD;
      interferon-stimulated gene (ISG) is a gene whose expression is stimulated by interferon.&#xD;
      Specifically, type I and type III interferons are antiviral cytokines, triggering ISGs that&#xD;
      combat viral infections. The type II interferon class only has one cytokine (IFN-γ), which&#xD;
      has some antiviral activity. To conclude, the assessment of gene expression for interferon α1&#xD;
      (IFNA1), interferon β1 (IFNB1), interferon γ (IFNG), interferon λ1 and λ2 (IFNL1 and IFNL2)&#xD;
      as well as for ACE2 and TMPRSS2 in sputum and nasal cells may shed new light on the course of&#xD;
      this infection in patient with AERD during long term aspirin therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2022</start_date>
  <completion_date type="Anticipated">February 28, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with two-fold decrease in gene expression of ACE2, TMPRSS2, BSG, PPIA, PPIB, DPP4, IFNA1, IFNB1 IFNG, IFNL1, IFNL2 and ISG in sputum and nasal cells after 8 weeks of placebo/aspirin therapy compared to the baseline value.</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>AERD - Aspirin Exacerbated Respiratory Disease</condition>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acard 300 mg (Acidum acetylsalicylicum). 1 tablet (300 mg) twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 tablet twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 300 Mg Oral Tablet</intervention_name>
    <description>8-week treatment of aspirin, then after 2-weeks washout the next treatment arm is placebo for 8 weeks</description>
    <arm_group_label>Aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>8-week treatment of placebo, then after 2-weeks washout the next treatment arm is aspirin for 8 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        INCLUSION CRITERIA FOR AERD PATIENTS:&#xD;
&#xD;
          -  signed informed consent form&#xD;
&#xD;
          -  18-70 years old AERD patients with baseline FEV1 of at least 70% of the predicted&#xD;
             value on the challenge/desensitization day&#xD;
&#xD;
          -  no pregnancy, higly effective contraception must be used&#xD;
&#xD;
        INCLUSION CRITERIA FOR HEALTHY CONTROL:&#xD;
&#xD;
          -  signed informed consent form&#xD;
&#xD;
          -  18-70 years old and healthy condition&#xD;
&#xD;
          -  no asthma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  failure of the circulatory and respiratory system, liver, kidneys and other vital&#xD;
             organs&#xD;
&#xD;
          -  diabetes, cancer, systemic diseases of connective tissue, infectious diseases,&#xD;
             coagulation disorders, active peptic ulcer disease, any active bleeding process.&#xD;
&#xD;
          -  Use of drugs that interact with aspirin&#xD;
&#xD;
          -  use of intoxicants, alcohol abuse, active and passive smoking,&#xD;
&#xD;
               -  pregnancy, lactation.&#xD;
&#xD;
               -  hypersensitivity to the active substance or any of the excipients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucyna Mastalerz, prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jagiellonian University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lucyna Mastalerz, prof.</last_name>
    <phone>12 40 03 050</phone>
    <email>lucyna.mastalerz@uj.edu.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital, Pulmunology Clinic</name>
      <address>
        <city>Kraków</city>
        <zip>30-688</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucyna Mastalerz, prof.</last_name>
      <phone>12 40 03 050</phone>
      <email>lucyna.mastalerz@uj.edu.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>March 1, 2023</study_first_submitted>
  <study_first_submitted_qc>March 28, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2023</study_first_posted>
  <last_update_submitted>April 4, 2023</last_update_submitted>
  <last_update_submitted_qc>April 4, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Jagiellonian University</investigator_affiliation>
    <investigator_full_name>Lucyna Mastalerz</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

